Kamada Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kamada Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kamada Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kamada Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kamada Pharmaceuticals (Kamada) is a biopharmaceutical company. It is developing specialty plasma-derived therapeutics. The company's product portfolio features critical care pharmaceuticals delivered via injection, infusion, and inhalation, as well as antiserums for treating snake bites. It includes treatments for immune thrombocytopenic purpura (ITP), post-exposure prophylaxis, and intravenous therapy for Alpha-1 Antitrypsin (AAT) deficiency. Kamada is developing a plasma-derived Hyperimmune IgG therapy for COVID-19, an Inhaled AAT program, and is also in early-stage development of recombinant AAT and liquid AAT for organ preservation. The company distributes its products through local health maintenance organizations (HMOs), hospitals, and pharmacies. Kamada is headquartered in Rehovot, Israel.
Headquarters
Israel
Address
P.O. Box 4081, 2 Holtzman Street, Science Park, Rehovot, 7670402
Website
www.kamada.com
Telephone
972 8 9406472
No of Employees
393
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KMDA (NASD)
Revenue (2024)
$180.5M
12.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.7%
(2024 vs 2023)
Market Cap*
$433.8M
Net Profit Margin (2024)
XYZ
24.5%
(2024 vs 2023)
* As of and is in US$
Kamada Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Kamrab/Kedrab: Prophylaxis of Rabies disease | Aerobika |
| Cytogam: Prophylaxis of Cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and heart/lung transplants | Bramitob |
| Varizig: Post-exposure prophylaxis of Varicella in high-risk individuals | Eligard |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In August, the company received approval from the US FDA for its Plasma Collection Center in Houston, Texas. |
| 2025 | Contracts/Agreements | In January, the company announced that it was awarded a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027. |
| 2024 | Corporate Changes/Expansions | In September, the company announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, Texas. |
Competitor Comparison
| Key Parameters | Kamada Ltd | Takeda Pharmaceutical Co Ltd | CSL Ltd | Kedrion SpA | Biotest AG |
|---|---|---|---|---|---|
| Headquarters | Israel | Japan | Australia | Italy | Germany |
| City | Rehovot | Chuo-Ku | Melbourne | Lucca | Dreieich |
| State/Province | - | Tokyo | Victoria | Toscana | Hessen |
| No. of Employees | 393 | 47,455 | 32,065 | 5,000 | 2,698 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lilach Asher Topilsky | Chairman | Executive Board | 2020 | 55 |
| Amir London | Chief Executive Officer | Senior Management | 2015 | 57 |
| Chaime Orlev | Chief Financial Officer | Senior Management | 2017 | 55 |
| Eran Nir | Chief Operating Officer | Senior Management | 2022 | 53 |
| Orit Pinchuk | Vice President - Regulatory Affairs | Senior Management | 2014 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer